Drug intelligence / Profile preview

atropine methylbromide

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral, Ophthalmic, Inhalation, Intravenous, Intramuscular
01

Overview

Atropine methylbromide is a quaternary ammonium salt derivative of atropine, classified as a muscarinic acetylcholine receptor antagonist. It acts by competitively inhibiting the action of acetylcholine at muscarinic receptors, thereby blocking parasympathetic nervous system activity. Due to its high polarity and inability to cross the blood-brain barrier, it primarily exerts peripheral effects with minimal central nervous system penetration. Clinically, it has been used as a mydriatic agent for pupil dilation during ophthalmic examinations and for relieving pyloric spasm in infants. Its peripheral antimuscarinic actions also make it useful in targeting smooth muscle and glandular tissues innervated by postganglionic cholinergic nerves[1][4][7].

Brand names
Eumydrin
Other names
atropine methylbromidemethylatropine bromideatropine methobromide
02

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)CHRM5 (M5)CHRM2 (M2)CHRM4 (M4)

Beyond the preview

Go deeper on atropine methylbromide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on atropine methylbromide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call